GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » PE Ratio

Biotech Acquisition Co (Biotech Acquisition Co) PE Ratio : 39.80 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-23), Biotech Acquisition Co's share price is $10.15. Biotech Acquisition Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $0.26. Therefore, Biotech Acquisition Co's PE Ratio for today is 39.80.

Biotech Acquisition Co's EPS (Diluted) for the three months ended in Sep. 2022 was $0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $0.26.

As of today (2024-05-23), Biotech Acquisition Co's share price is $10.15. Biotech Acquisition Co's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $0.26. Therefore, Biotech Acquisition Co's PE Ratio without NRI ratio for today is 39.80.

Biotech Acquisition Co's EPS without NRI for the three months ended in Sep. 2022 was $0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $0.26.

Biotech Acquisition Co's EPS (Basic) for the three months ended in Sep. 2022 was $0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $0.26.

Back to Basics: PE Ratio


Biotech Acquisition Co PE Ratio Historical Data

The historical data trend for Biotech Acquisition Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co PE Ratio Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
PE Ratio
N/A At Loss

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PE Ratio Get a 7-Day Free Trial Premium Member Only 243.50 At Loss At Loss 31.43 38.90

Competitive Comparison of Biotech Acquisition Co's PE Ratio

For the Shell Companies subindustry, Biotech Acquisition Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Acquisition Co's PE Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's PE Ratio falls into.



Biotech Acquisition Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Biotech Acquisition Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=10.15/0.255
=39.8

Biotech Acquisition Co's Share Price of today is $10.15.
Biotech Acquisition Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Biotech Acquisition Co  (NAS:BIOT) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Biotech Acquisition Co PE Ratio Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By Stock market mentor Stock market mentor 02-02-2023